BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG. Borderline Mean Pulmonary Artery Pressure in Patients With Systemic Sclerosis: Transpulmonary Gradient Predicts Risk of Developing Pulmonary Hypertension: Borderline Mean PAP and Risk of PH in SSc. Arthritis & Rheumatism 2013;65:1074-84. [DOI: 10.1002/art.37838] [Cited by in Crossref: 104] [Cited by in F6Publishing: 89] [Article Influence: 11.6] [Reference Citation Analysis]
Number Citing Articles
1 Condliffe R, Kovacs G. Identifying early pulmonary arterial hypertension in patients with systemic sclerosis. Eur Respir J 2018;51:1800495. [PMID: 29618608 DOI: 10.1183/13993003.00495-2018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Weatherald J, Montani D, Jevnikar M, Jaïs X, Savale L, Humbert M. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2019;28:190023. [PMID: 31366460 DOI: 10.1183/16000617.0023-2019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 7.3] [Reference Citation Analysis]
3 Albinni S, Marx M, Lang IM. Focused Update on Pulmonary Hypertension in Children-Selected Topics of Interest for the Adult Cardiologist. Medicina (Kaunas) 2020;56:E420. [PMID: 32825190 DOI: 10.3390/medicina56090420] [Reference Citation Analysis]
4 Condliffe R. Unmasking hidden disease: exercise pulmonary haemodynamics in systemic sclerosis. Eur Respir J 2017;50:1700885. [DOI: 10.1183/13993003.00885-2017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
5 Kovacs G, Olschewski H. Borderline pulmonary pressures in scleroderma - a 'pre-pulmonary arterial hypertension' condition? Arthritis Res Ther 2015;17:123. [PMID: 25981512 DOI: 10.1186/s13075-015-0649-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
6 Sugawara E, Kato M, Sato T, Takahashi K, Kono M, Hisada R, Kono M, Oku K, Bohgaki T, Yasuda S, Tsujino I, Tanaka S, Atsumi T. Diversity of borderline pulmonary arterial pressure associated with systemic sclerosis: 3 case series. Modern Rheumatology Case Reports 2017;1:9-14. [DOI: 10.1080/24725625.2016.1259722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Beshay S, Sahay S, Humbert M. Evaluation and management of pulmonary arterial hypertension. Respir Med 2020;171:106099. [PMID: 32829182 DOI: 10.1016/j.rmed.2020.106099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Escribano Subías P, Aurtenetxe Pérez A, Pérez Olivares C, Gómez Climent L, Diago Cabezudo JI, Perelló MF. Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. Expert Rev Respir Med 2021;15:493-504. [PMID: 33472458 DOI: 10.1080/17476348.2021.1878027] [Reference Citation Analysis]
9 Adamopoulos D, Pagoulatou S, Rovas G, Bikia V, Müller H, Giannakopoulos G, Mauler-wittwer S, Licker M, Stergiopulos N, Lador F, Noble S. Prognostic Implications of the Novel Pulmonary Hypertension Definition in Patients with Aortic Stenosis after Transcatheter Valve Replacement. JCM 2022;11:4279. [DOI: 10.3390/jcm11154279] [Reference Citation Analysis]
10 Maron BA, Wertheim BM, Gladwin MT. Under Pressure to Clarify Pulmonary Hypertension Clinical Risk. Am J Respir Crit Care Med 2018;197:423-6. [PMID: 29216444 DOI: 10.1164/rccm.201711-2306ED] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
11 Ruopp NF, Farber HW. The New World Symposium on Pulmonary Hypertension Guidelines: Should Twenty-One Be the New Twenty-Five? Circulation 2019;140:1134-6. [DOI: 10.1161/circulationaha.119.040292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Elia D, Caminati A, Zompatori M, Cassandro R, Lonati C, Luisi F, Pelosi G, Provencher S, Harari S. Pulmonary hypertension and chronic lung disease: where are we headed? Eur Respir Rev 2019;28:190065. [DOI: 10.1183/16000617.0065-2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
13 Ratwatte S, Anderson J, Strange G, Corrigan C, Collins N, Celermajer DS, Dwyer N, Feenstra J, Keating D, Kotlyar E, Lavender M, Whitford H, Whyte K, Williams T, Wrobel JP, Keogh A, Lau EM; PHSANZ Registry. Pulmonary arterial hypertension with below threshold pulmonary vascular resistance. Eur Respir J 2020;56:1901654. [PMID: 32341105 DOI: 10.1183/13993003.01654-2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Sarı A, Şener YZ, Armağan B, Kılıç L, Kaya EB, Hekimsoy V, Karadağ Ö, Apras Bilgen Ş, Kiraz S, Ertenli I, Tokgozoğlu L, Akdoğan A. How did the updated hemodynamic definitions affect the frequency of pulmonary hypertension in patients with systemic sclerosis? Anatol J Cardiol 2021;25:30-5. [PMID: 33382047 DOI: 10.14744/AnatolJCardiol.2020.46625] [Reference Citation Analysis]
15 Leuchte HH, Halank M, Held M, Borst M, Ewert R, Klose H, Lange TJ, Meyer FJ, Skowasch D, Wilkens H, Seyfarth HJ. [Differential Diagnosis of Pulmonary Hypertension Using the Example of Collagenosis-associated PAH in the Context of Chronic Lung and Left Heart Disease]. Pneumologie 2021;75:122-37. [PMID: 33578434 DOI: 10.1055/a-1204-3248] [Reference Citation Analysis]
16 Takahashi K, Taniguchi H, Ando M, Sakamoto K, Kondoh Y, Watanabe N, Kimura T, Kataoka K, Suzuki A, Ito S, Hasegawa Y. Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study. BMC Pulm Med 2016;16:55. [PMID: 27094018 DOI: 10.1186/s12890-016-0207-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
17 Hirani N, Brunner NW, Kapasi A, Chandy G, Rudski L, Paterson I, Langleben D, Mehta S, Mielniczuk L. Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. Canadian Journal of Cardiology 2020;36:977-92. [DOI: 10.1016/j.cjca.2019.11.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
18 Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol 2019;46:176-83. [PMID: 30275260 DOI: 10.3899/jrheum.180018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
19 Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685-1699. [PMID: 28413064 DOI: 10.1016/s0140-6736(17)30933-9] [Cited by in Crossref: 580] [Cited by in F6Publishing: 245] [Article Influence: 116.0] [Reference Citation Analysis]
20 Asari Y, Yamasaki Y, Tsuchida K, Suzuki K, Akashi YJ, Okazaki T, Ozaki S, Yamada H, Kawahata K. Hemodynamic heterogeneity of connective tissue disease patients with borderline mean pulmonary artery pressure and its distinctive characters from those with normal pulmonary artery pressure: a retrospective study. Clin Rheumatol 2018;37:3373-80. [PMID: 29777409 DOI: 10.1007/s10067-018-4142-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Kovacs G, Dumitrescu D, Barner A, Greiner S, Grünig E, Hager A, Köhler T, Kozlik-feldmann R, Kruck I, Lammers AE, Mereles D, Meyer A, Meyer J, Pabst S, Seyfarth H, Sinning C, Sorichter S, Stähler G, Wilkens H, Held M. Definition, clinical classification and initial diagnosis of pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology 2018;272:11-9. [DOI: 10.1016/j.ijcard.2018.08.083] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
22 Aithala R, Alex AG, Danda D. Pulmonary hypertension in connective tissue diseases: an update. Int J Rheum Dis 2017;20:5-24. [PMID: 28205373 DOI: 10.1111/1756-185X.13001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 4.6] [Reference Citation Analysis]
23 Kolte D, Lakshmanan S, Jankowich MD, Brittain EL, Maron BA, Choudhary G. Mild Pulmonary Hypertension Is Associated With Increased Mortality: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2018;7:e009729. [PMID: 30371195 DOI: 10.1161/JAHA.118.009729] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
24 Gilbane AJ, Derrett-smith E, Trinder SL, Good RB, Pearce A, Denton CP, Holmes AM. Impaired Bone Morphogenetic Protein Receptor II Signaling in a Transforming Growth Factor-β–Dependent Mouse Model of Pulmonary Hypertension and in Systemic Sclerosis. Am J Respir Crit Care Med 2015;191:665-77. [DOI: 10.1164/rccm.201408-1464oc] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
25 Zou RH, Wallace WD, Nouraie SM, Chan SY, Risbano MG. Lower DLco% identifies exercise pulmonary hypertension in patients with parenchymal lung disease referred for dyspnea. Pulm Circ 2020;10:2045894019891912. [PMID: 32128158 DOI: 10.1177/2045894019891912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Simonneau G, Hoeper MM. The revised definition of pulmonary hypertension: exploring the impact on patient management. Eur Heart J Suppl 2019;21:K4-8. [PMID: 31857795 DOI: 10.1093/eurheartj/suz211] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
27 Sahay S. Evaluation and classification of pulmonary arterial hypertension. J Thorac Dis 2019;11:S1789-99. [PMID: 31632756 DOI: 10.21037/jtd.2019.08.54] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
28 Tanyeri S, Akbal OY, Keskin B, Hakgor A, Karagoz A, Tokgoz HC, Dogan C, Bayram Z, Kulahcioglu S, Erdogan E, Balaban I, Ceneli D, Acar RD, Tanboga IH, Ozdemir N, Kaymaz C. Impact of the updated hemodynamic definitions on diagnosis rates of pulmonary hypertension. Pulm Circ 2020;10:2045894020931299. [PMID: 32922744 DOI: 10.1177/2045894020931299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Douschan P, Kovacs G, Avian A, Foris V, Gruber F, Olschewski A, Olschewski H. Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality. Am J Respir Crit Care Med 2018;197:509-16. [PMID: 29099619 DOI: 10.1164/rccm.201706-1215OC] [Cited by in Crossref: 77] [Cited by in F6Publishing: 35] [Article Influence: 25.7] [Reference Citation Analysis]
30 Lau EMT, Humbert M, Celermajer DS. Early detection of pulmonary arterial hypertension. Nat Rev Cardiol 2015;12:143-55. [DOI: 10.1038/nrcardio.2014.191] [Cited by in Crossref: 79] [Cited by in F6Publishing: 60] [Article Influence: 9.9] [Reference Citation Analysis]
31 Coirier V, Chabanne C, Jouneau S, Belhomme N, Ballerie A, Cazalets C, Sobanski V, Hachulla É, Jégo P, Lescoat A. Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team. Diagnostics (Basel) 2021;11:1738. [PMID: 34679436 DOI: 10.3390/diagnostics11101738] [Reference Citation Analysis]
32 Ninagawa K, Kato M, Nakamura H, Abe N, Kono M, Fujieda Y, Oku K, Yasuda S, Ohira H, Tsujino I, Atsumi T. Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis. Rheumatol Int 2019;39:1883-7. [DOI: 10.1007/s00296-019-04370-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Hewes JL, Lee JY, Fagan KA, Bauer NN. The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers. Pulm Circ 2020;10:2045894019892801. [PMID: 32110383 DOI: 10.1177/2045894019892801] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
34 Becker MO, Riemekasten G. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. Expert Rev Clin Immunol 2016;12:115-35. [PMID: 26558747 DOI: 10.1586/1744666X.2016.1115717] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
35 Hoeper MM, Humbert M. The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally! Eur Respir J 2019;53:1900038. [DOI: 10.1183/13993003.00038-2019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
36 Hoffmann-vold A, Fretheim H, Midtvedt Ø, Kilian K, Angelshaug M, Chaudhary A, Gunnarsson R, Brunborg C, Garen T, Andreassen AK, Gude E, Molberg Ø. Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort. Rheumatology 2018;57:480-7. [DOI: 10.1093/rheumatology/kex435] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
37 Frerix M, Meier F, Hermann W, Müller-ladner U. Therapeutische Strategien im Frühstadium der systemischen Sklerose: Frühe Diagnose – frühe Symptome – frühe Probleme. Z Rheumatol 2013;72:960-9. [DOI: 10.1007/s00393-013-1270-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913. [PMID: 30545968 DOI: 10.1183/13993003.01913-2018] [Cited by in Crossref: 957] [Cited by in F6Publishing: 825] [Article Influence: 319.0] [Reference Citation Analysis]
39 Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Seminars in Arthritis and Rheumatism 2014;44:55-62. [DOI: 10.1016/j.semarthrit.2014.03.002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
40 Assad TR, Maron BA, Robbins IM, Xu M, Huang S, Harrell FE, Farber-Eger EH, Wells QS, Choudhary G, Hemnes AR, Brittain EL. Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. JAMA Cardiol 2017;2:1361-8. [PMID: 29071338 DOI: 10.1001/jamacardio.2017.3882] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 22.0] [Reference Citation Analysis]
41 Haque A, Kiely DG, Kovacs G, Thompson AAR, Condliffe R. Pulmonary hypertension phenotypes in patients with systemic sclerosis. Eur Respir Rev 2021;30:210053. [PMID: 34407977 DOI: 10.1183/16000617.0053-2021] [Reference Citation Analysis]
42 Huston JH, Frantz RP, Brittain EL. Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms? Pulm Circ 2019;9:2045894019845615. [PMID: 30931829 DOI: 10.1177/2045894019844994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
43 Adrovic A, Oztunc F, Barut K, Koka A, Gojak R, Sahin S, Demir T, Kasapcopur O. The frequency of pulmonary hypertension in patients with juvenile scleroderma. Bosn J Basic Med Sci 2015;15:30-5. [PMID: 26614849 DOI: 10.17305/bjbms.2015.596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
44 Guillén-Del Castillo A, Callejas-Moraga EL, García G, Rodríguez-Palomares JF, Román A, Berastegui C, López-Meseguer M, Domingo E, Fonollosa-Plá V, Simeón-Aznar CP. High sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center. Arthritis Res Ther 2017;19:135. [PMID: 28615037 DOI: 10.1186/s13075-017-1327-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
45 Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, Garcia G, Grünig E, Howard L, Humbert M, Lau E, Laveneziana P, Lewis GD, Naeije R, Peacock A, Rosenkranz S, Saggar R, Ulrich S, Vizza D, Vonk Noordegraaf A, Olschewski H. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J 2017;50:1700578. [DOI: 10.1183/13993003.00578-2017] [Cited by in Crossref: 119] [Cited by in F6Publishing: 86] [Article Influence: 23.8] [Reference Citation Analysis]
46 van Riel ACMJ, Systrom DM, Oliveira RKF, Landzberg MJ, Mulder BJM, Bouma BJ, Maron BA, Shah AM, Waxman AB, Opotowsky AR. Hemodynamic and metabolic characteristics associated with development of a right ventricular outflow tract pressure gradient during upright exercise. PLoS One 2017;12:e0179053. [PMID: 28636647 DOI: 10.1371/journal.pone.0179053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
47 Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology 2013;62:D34-41. [DOI: 10.1016/j.jacc.2013.10.029] [Cited by in Crossref: 1761] [Cited by in F6Publishing: 1454] [Article Influence: 195.7] [Reference Citation Analysis]
48 Mathai SC. Pulmonary Hypertension Associated with Connective Tissue Disease. Cardiol Clin 2022;40:29-43. [PMID: 34809915 DOI: 10.1016/j.ccl.2021.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Mejía Chew C, Batres S, Ríos Blanco J. Update on pulmonary arterial hypertension. Revista Clínica Española (English Edition) 2016;216:436-44. [DOI: 10.1016/j.rceng.2016.05.001] [Reference Citation Analysis]
50 Vonk MC, Vandecasteele E, van Dijk AP. Pulmonary hypertension in connective tissue diseases, new evidence and challenges. Eur J Clin Invest 2021;51:e13453. [PMID: 33216992 DOI: 10.1111/eci.13453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Sharma M, Burns AT, Yap K, Prior DL. The role of imaging in pulmonary hypertension. Cardiovasc Diagn Ther 2021;11:859-80. [PMID: 34295710 DOI: 10.21037/cdt-20-295] [Reference Citation Analysis]
52 Kato M, Atsumi T. Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects. Eur J Clin Invest 2018;48. [PMID: 29285766 DOI: 10.1111/eci.12876] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
53 Suzuki A, Taniguchi H, Watanabe N, Kondoh Y, Kimura T, Kataoka K, Matsuda T, Yokoyama T, Sakamoto K, Nishiyama O, Hasegawa Y. Significance of pulmonary arterial pressure as a prognostic indicator in lung-dominant connective tissue disease. PLoS One 2014;9:e108339. [PMID: 25268705 DOI: 10.1371/journal.pone.0108339] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
54 Gelzinis TA. Pulmonary Hypertension in 2021: Part I-Definition, Classification, Pathophysiology, and Presentation. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00572-3. [PMID: 34344595 DOI: 10.1053/j.jvca.2021.06.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
55 Condliffe R, Howard LS. Connective tissue disease-associated pulmonary arterial hypertension. F1000Prime Rep 2015;7:06. [PMID: 25705389 DOI: 10.12703/P7-06] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
56 Lau EM, Godinas L, Sitbon O, Montani D, Savale L, Jaïs X, Lador F, Gunther S, Celermajer DS, Simonneau G, Humbert M, Chemla D, Herve P. Resting pulmonary artery pressure of 21–24 mmHg predicts abnormal exercise haemodynamics. Eur Respir J 2016;47:1436-44. [DOI: 10.1183/13993003.01684-2015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
57 Quinlivan A, Ross L, Proudman S. Systemic sclerosis: Advances towards stratified medicine. Best Pract Res Clin Rheumatol 2020;34:101469. [PMID: 31973938 DOI: 10.1016/j.berh.2019.101469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kovacs G, Maron BA. The assessment of pulmonary arterial pressure and its clinical relevance: a 100-year journey from Europe, over the United States to Australia. Eur Respir J 2022;59:2102064. [PMID: 34972686 DOI: 10.1183/13993003.02064-2021] [Reference Citation Analysis]
59 Valenzuela A, Nandagopal S, Steen VD, Chung L. Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. Rheum Dis Clin North Am 2015;41:489-506. [PMID: 26210131 DOI: 10.1016/j.rdc.2015.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
60 Provencher S, Boucherat O, Potus F, Bonnet S. Pulmonary hypertension thresholds: time to lower further? Lancet Respir Med 2020;8:834-6. [PMID: 32730751 DOI: 10.1016/S2213-2600(20)30326-X] [Reference Citation Analysis]
61 Visovatti SH, Distler O, Coghlan JG, Denton CP, Grünig E, Bonderman D, Müller-Ladner U, Pope JE, Vonk MC, Seibold JR, Torres-Martin JV, Doelberg M, Chadha-Boreham H, Rosenberg DM, McLaughlin VV, Khanna D. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther 2014;16:493. [PMID: 25491468 DOI: 10.1186/s13075-014-0493-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
62 Mejía Chew CR, Alcolea Batres S, Ríos Blanco JJ. Update in pulmonary arterial hypertension. Rev Clin Esp (Barc) 2016;216:436-44. [PMID: 27156166 DOI: 10.1016/j.rce.2016.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Barberà JA, Román A, Gómez-Sánchez MÁ, Blanco I, Otero R, López-Reyes R, Otero I, Pérez-Peñate G, Sala E, Escribano P. Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. Arch Bronconeumol (Engl Ed) 2018;54:205-15. [PMID: 29472044 DOI: 10.1016/j.arbres.2017.11.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
64 Vanhentenrijk S, Verbrugge FH. New Hemodynamic Insights in Pulmonary Vascular Disease and Heart Failure with Preserved Ejection Fraction. Curr Treat Options Cardio Med 2021;23. [DOI: 10.1007/s11936-021-00900-x] [Reference Citation Analysis]
65 Sarwahi V, Galina J, Atlas A, Gecelter R, Hasan S, Amaral TD, Maguire K, Lo Y, Kalantre S. Scoliosis Surgery Normalizes Cardiac Function in Adolescent Idiopathic Scoliosis Patients. Spine (Phila Pa 1976) 2021;46:E1161-7. [PMID: 34618708 DOI: 10.1097/BRS.0000000000004060] [Reference Citation Analysis]
66 Shaikh F, Anklesaria Z, Shagroni T, Saggar R, Gargani L, Bossone E, Ryan M, Channick R, Saggar R. A review of exercise pulmonary hypertension in systemic sclerosis. J Scleroderma Relat Disord 2019;4:225-37. [PMID: 35382504 DOI: 10.1177/2397198319851653] [Reference Citation Analysis]
67 Brusca SB, Zou Y, Elinoff JM. How low should we go? Potential benefits and ramifications of the pulmonary hypertension hemodynamic definitions proposed by the 6th World Symposium. Curr Opin Pulm Med 2020;26:384-90. [PMID: 32701671 DOI: 10.1097/MCP.0000000000000699] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Demerouti E, Tsangaris I, Dimitroulas T, Giannakoulas G, Katsimpri P, Mitrouska I, Orfanos S, Skoularigkis I, Voulgari P, Sfikakis P. Pulmonary Arterial Hypertension in Connective Tissue Disorders: The emerging role of screening and early diagnosis. A position paper for Greek Rheumatologists. Mediterr J Rheumatol 2019;30:90-3. [PMID: 32185347 DOI: 10.31138/mjr.30.2.90] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Nagel C, Marra AM, Benjamin N, Blank N, Cittadini A, Coghlan G, Distler O, Denton CP, Egenlauf B, Fiehn C, Fischer C, Harutyunova S, Hoeper MM, Lorenz HM, Xanthouli P, Bossone E, Grünig E. Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. Arthritis Rheumatol 2019;71:805-16. [PMID: 30615302 DOI: 10.1002/art.40814] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
70 Sung YK, Chung L. Connective tissue disease-associated pulmonary arterial hypertension. Rheum Dis Clin North Am 2015;41:295-313. [PMID: 25836644 DOI: 10.1016/j.rdc.2015.01.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
71 Iudici M, Allali D, Porcher R. Correspondence on 'Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension'. Ann Rheum Dis 2020:annrheumdis-2020-219568. [PMID: 33328253 DOI: 10.1136/annrheumdis-2020-219568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Sommer N, Ghofrani HA, Pak O, Bonnet S, Provencher S, Sitbon O, Rosenkranz S, Hoeper MM, Kiely DG. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol 2021;178:6-30. [PMID: 32034759 DOI: 10.1111/bph.15016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
73 Kovacs G, Douschan P, Maron BA, Condliffe R, Olschewski H. Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis? Eur J Heart Fail 2019;21:1057-61. [DOI: 10.1002/ejhf.1570] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
74 Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, Marra AM, Benjamin N, Fischer C, Grünig E. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J 2018;51:1701197. [PMID: 29563168 DOI: 10.1183/13993003.01197-2017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
75 Xanthouli P, Jordan S, Milde N, Marra A, Blank N, Egenlauf B, Gorenflo M, Harutyunova S, Lorenz HM, Nagel C, Theobald V, Lichtblau M, Berlier C, Ulrich S, Grünig E, Benjamin N, Distler O. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis 2020;79:370-8. [PMID: 31818805 DOI: 10.1136/annrheumdis-2019-216476] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
76 Yagi M, Taniguchi H, Kondoh Y, Ando M, Kimura T, Kataoka K, Furukawa T, Suzuki A, Johkoh T, Hasegawa Y. CT-determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis. Respirology 2017;22:1393-9. [PMID: 28488784 DOI: 10.1111/resp.13066] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
77 Jaafar S, Visovatti S, Young A, Huang S, Cronin P, Vummidi D, McLaughlin V, Khanna D. Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. Eur Respir J 2019;54:1900586. [PMID: 31196948 DOI: 10.1183/13993003.00586-2019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
78 Bernardo RJ, Bokan A, Ramjug S. Updates in pulmonary hypertension and other pulmonary vascular diseases. Breathe (Sheff) 2019;15:241-3. [PMID: 31508162 DOI: 10.1183/20734735.0187-2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Kovacs G. Response. Chest 2021;160:e541. [PMID: 34743864 DOI: 10.1016/j.chest.2021.07.014] [Reference Citation Analysis]
80 Jiang R, Liu H, Pudasaini B, Zhang R, Xu JL, Wang L, Zhao QH, Yuan P, Guo J, He J, Gong SG, Wu C, Wu WH, Luo CJ, Qiu HL, Jing ZC, Liu JM. Characteristics of cardiopulmonary exercise testing of patients with borderline mean pulmonary artery pressure. Clin Respir J 2019;13:148-58. [PMID: 30667180 DOI: 10.1111/crj.12996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
81 Thakkar V, Lau EM. Connective tissue disease-related pulmonary arterial hypertension. Best Pract Res Clin Rheumatol 2016;30:22-38. [PMID: 27421214 DOI: 10.1016/j.berh.2016.03.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
82 Coghlan JG, Bogaard HJ. Exercise pulmonary haemodynamics: a test in search of purpose. Eur Respir J 2016;47:1315-7. [PMID: 27132262 DOI: 10.1183/13993003.00397-2016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
83 Pfeuffer-Jovic E, Weiner S, Wilkens H, Schmitt D, Frantz S, Held M. Impact of the new definition of pulmonary hypertension according to world symposium of pulmonary hypertension 2018 on diagnosis of post-capillary pulmonary hypertension. Int J Cardiol 2021;335:105-10. [PMID: 33823213 DOI: 10.1016/j.ijcard.2021.04.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
84 Farge D, Burt RK, Oliveira MC, Mousseaux E, Rovira M, Marjanovic Z, de Vries-Bouwstra J, Del Papa N, Saccardi R, Shah SJ, Lee DC, Denton C, Alexander T, Kiely DG, Snowden JA. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant 2017;52:1495-503. [PMID: 28530671 DOI: 10.1038/bmt.2017.56] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 11.6] [Reference Citation Analysis]
85 Lamia B, Muir JF, Molano LC, Viacroze C, Benichou J, Bonnet P, Quieffin J, Cuvelier A, Naeije R. Altered synchrony of right ventricular contraction in borderline pulmonary hypertension. Int J Cardiovasc Imaging 2017;33:1331-9. [PMID: 28317064 DOI: 10.1007/s10554-017-1110-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
86 Fouad J, Joseph P. The Evolution in Nomenclature, Diagnosis, and Classification of Pulmonary Hypertension. Clin Chest Med 2021;42:1-8. [PMID: 33541603 DOI: 10.1016/j.ccm.2020.11.012] [Reference Citation Analysis]
87 Kovacs G, Olschewski H. The definition of pulmonary hypertension: history, practical implications and current controversies. Breathe (Sheff) 2021;17:210076. [PMID: 35035548 DOI: 10.1183/20734735.0076-2021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Zanatta E, Codullo V, Avouac J, Allanore Y. Systemic sclerosis: Recent insight in clinical management. Joint Bone Spine 2020;87:293-9. [PMID: 31568838 DOI: 10.1016/j.jbspin.2019.09.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
89 Reiter G, Reiter U, Kovacs G, Olschewski H, Fuchsjäger M. Blood flow vortices along the main pulmonary artery measured with MR imaging for diagnosis of pulmonary hypertension. Radiology 2015;275:71-9. [PMID: 25372980 DOI: 10.1148/radiol.14140849] [Cited by in Crossref: 75] [Cited by in F6Publishing: 56] [Article Influence: 9.4] [Reference Citation Analysis]
90 Gibbs JSR, Torbicki A. Proposed new pulmonary hypertension definition: is 4 mm(Hg) worth re-writing medical textbooks? Eur Respir J 2019;53:1900197. [PMID: 30923179 DOI: 10.1183/13993003.00197-2019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
91 Kato M, Sugimoto A, Atsumi T. Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. Expert Rev Clin Immunol 2020;16:993-1004. [PMID: 32975145 DOI: 10.1080/1744666X.2021.1825940] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Vizza CD, Ghio S, Badagliacca R, Manzi G, Scelsi L, Argiento P, D'Alto M. Gaps of evidence in pulmonary arterial hypertension. Int J Cardiol 2022:S0167-5273(22)00925-1. [PMID: 35716936 DOI: 10.1016/j.ijcard.2022.06.026] [Reference Citation Analysis]
93 Ferreira AC, Serejo JS, Durans R, Pereira Costa JM, Maciel AWS, Vieira ASM, Dias-Filho CAA, Dias CJ, Bomfim MRQ, Mostarda CT, Brito-Monzani JO. Dose-related Effects of Resveratrol in Different Models of Pulmonary Arterial Hypertension: A Systematic Review. Curr Cardiol Rev 2020;16:231-40. [PMID: 31797762 DOI: 10.2174/1573403X15666191203110554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Volkov AV, Kurmukov IA, Yudkina NN, Glukhova SI, Nikolaeva EV. [Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis]. Ter Arkh 2015;87:49-56. [PMID: 25823269 DOI: 10.17116/terarkh201587149-56] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
95 Condon DF, Nickel NP, Anderson R, Mirza S, de Jesus Perez VA. The 6th World Symposium on Pulmonary Hypertension: what's old is new. F1000Res 2019;8:F1000 Faculty Rev-888. [PMID: 31249672 DOI: 10.12688/f1000research.18811.1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
96 Sundaram SM, Chung L. An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature. Curr Rheumatol Rep 2018;20:10. [PMID: 29488016 DOI: 10.1007/s11926-018-0709-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
97 Thakkar V, Nikpour M, Stevens WM, Proudman SM. Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension: Pulmonary hypertension in scleroderma. Intern Med J 2015;45:248-54. [DOI: 10.1111/imj.12691] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
98 Denton CP, Wells AU, Coghlan JG. Major lung complications of systemic sclerosis. Nat Rev Rheumatol 2018;14:511-27. [DOI: 10.1038/s41584-018-0062-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
99 Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, Müller-Ladner U, Pope JE, Vonk MC, Doelberg M. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340-1349. [PMID: 23687283 DOI: 10.1136/annrheumdis-2013-203301] [Cited by in Crossref: 386] [Cited by in F6Publishing: 316] [Article Influence: 42.9] [Reference Citation Analysis]
100 Heresi GA, Minai OA, Tonelli AR, Hammel JP, Farha S, Parambil JG, Dweik RA. Clinical characterization and survival of patients with borderline elevation in pulmonary artery pressure. Pulm Circ 2013;3:916-25. [PMID: 25006408 DOI: 10.1086/674756] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
101 Gerges M, Yacoub M. Chronic thromboembolic pulmonary hypertension - still evolving. Glob Cardiol Sci Pract 2020;2020:e202011. [PMID: 33150155 DOI: 10.21542/gcsp.2020.11] [Reference Citation Analysis]
102 Vilela VS, Dias MM, Salgado ÂA, da Silva BRA, Lopes AJ, Bessa EJC, Bruno LP, da Costa CH, Levy RA, Rufino R. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up. BMC Pulm Med 2021;21:251. [PMID: 34325685 DOI: 10.1186/s12890-021-01618-z] [Reference Citation Analysis]
103 Kovacs G, Avian A, Tscherner M, Foris V, Bachmaier G, Olschewski A, Olschewski H. Characterization of Patients With Borderline Pulmonary Arterial Pressure. Chest 2014;146:1486-93. [DOI: 10.1378/chest.14-0194] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
104 Xue L, Yang Y, Sun B, Liu B, Zeng Q, Xiong C. Mildly Elevated Pulmonary Arterial Pressure Is Associated With a High Risk of Progression to Pulmonary Hypertension and Increased Mortality: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2021;10:e018374. [PMID: 33754797 DOI: 10.1161/JAHA.120.018374] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Coghlan JG. Editorial: Stress Echocardiography and Cochin Risk Prediction Score for the Prediction of Pulmonary Arterial Hypertension in Scleroderma: Not yet Ready for Prime Time: Editorial. Arthritis & Rheumatism 2013;65:2236-9. [DOI: 10.1002/art.38040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
106 Tsuchida K, Yamada H, Yamasaki Y, Suzuki K, Kongoji K, Akashi Y, Ozaki S. Left heart abnormalities in connective tissue disease patients with pre-capillary pulmonary hypertension as well as borderline mean pulmonary arterial pressure. Mod Rheumatol 2015;25:744-7. [PMID: 25736353 DOI: 10.3109/14397595.2015.1005871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]